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Summary This paper describes a case of lung injury attributed to the use of
Nitrofurantoin and a review of the relevant literature. An 88-year-old woman was
admitted to the ﬂoor for the evaluation of recent symptoms of dyspnea, fatigue and
productive cough. She was initiated on nitrofurantoin 300mg per day for the treat-
ment of a urinary tract infection 3 days earlier. Upon examination, chest auscultation
revealed bilateral inspiratory crackles. Chest radiograph showed bilateral airspace
and interstitial inﬁltrates. Laboratory studies revealed an elevated white blood
cell count of 13,500/L (reference range = 5200—12,400/L) and blood eosinophilia
(10%, reference range: 0—7%). Using clinical judgment and the algorithm of Naranjo,
it was determined that nitrofurantoin use was the probable cause of the patient’s
lung injury. Symptomatic improvement was observed shortly after the drug was
discontinued. A review of information from several European and North American
pharmacovigilance databases (through June 2014) identiﬁed several reports of sus-
pected nitrofurantoin-induced toxicity, including reports of acute toxicity reactions,
which were related in many ways to the case we are reporting here.
© 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Limited. All rights reserved.
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to all ﬂuoroquinolones and most beta-lactams. TheIntroduction
According to the latest guidelines from the Infec-
tious Diseases Society of America and the European
Society of Microbiology and Infectious Diseases,
nitrofurantoin is one of the recommended ﬁrst line
medications for the treatment of acute uncompli-
cated cystitis, an often recurrent and problematic
condition encountered in women [1]. Consequently,
the use of nitrofurantoin increased markedly
mainly due to its minimal bacterial resistance and
decreased propensity for collateral damage [1].
We performed a comprehensive search
of PubMed, MEDLINE, EMBASE, and Google
Scholar databases using various combinations
of the keywords ‘‘nitrofurantoin’’, ‘‘lung’’,
‘‘toxicity’’, ‘‘acute’’, ‘‘induced’’, ‘‘pulmonary’’,
‘‘treatment’’, ‘‘prophylaxis’’, and ‘‘reaction’’ and
reviewed 15 reports of nitrofurantoin-induced lung
toxicity cases. These showed that nitrofurantoin
has been associated with acute, subacute and
chronic pulmonary adverse reactions [2—9]. The
ﬁrst case of acute pulmonary toxicity to nitrofu-
rantoin demonstrating a clear cause-and-effect
relationship by intentional rechallenge with the
drug was reported by Israel and Diamond in 1962
[10]. Although generally a rare risk, because of
the increased use of the drug, nitrofurantoin
reactions are some of the commonly encountered
and reported pulmonary drug toxicities in practice.
In a study published in the CHEST journal in 1989,
Susan S. Jick et al. attempted to estimate the
frequency of acute and chronic pulmonary reac-
tions serious enough to warrant hospitalizations
following the use of nitrofurantoin at a large
health maintenance organization and concluded
that nitrofurantoin may cause acute severe pul-
monary illnesses approximately once in every 5000
ﬁrst administrations and ﬁbrosis serious enough to
warrant hospitalization in approximately one in 750
long-term users who had multiple prescriptions of
nitrofurantoin for at least 2 years [11]. The acute
pulmonary reactions represented approximately
90% of adverse pulmonary reactions and exhibited
the characteristics of an allergic reaction, while
it was suggested that chronic pulmonary reactions
may be caused by a toxic mechanism [12]. Chronic
reactions do not follow upon acute reactions, nor
s
p
so acute reactions predispose to chronic ones,
ut early recognition of the reactions and quick
ithdrawal of the drug are necessary in both forms
13]. Furthermore, it has been shown that the risk
f an adverse reaction increases with the patient’s
ge and is higher in women than in men [13].
linically, the acute reaction is characterized by
ever, shortness of breath, cough and peripheral
osinophilia, usually within days to a few weeks
f drug initiation [14]. Chronic nitrofurantoin
oxicity is typically associated with cough and
lowly progressive dyspnea manifesting months to
ears after initiating therapy. Histologically, both
orms manifest with a wide pattern of histolog-
cal reactions including pulmonary ﬁbrosis [15].
nfortunately, nitrofurantoin-induced pulmonary
oxicity is largely under-recognized, which may
nnecessarily prolong patient exposure and lead
o irreversible pulmonary complications [16]. This
erhaps warrants the consideration of alternative
ntimicrobial agents with higher beneﬁt-to-risk
atios in certain patient populations. Patients
uffering serious adverse reactions to nitrofu-
antoin should also carry written warnings about
e-exposure.
Here, we present one highly probable case, as
etermined by the Naranjo adverse drug reaction
robability scale score, of nitrofurantoin-induced
cute pulmonary reaction in an 88-year-old woman
ho took nitrofurantoin for the treatment of a uri-
ary tract infection [17].
ase description
n 88-year-old previously healthy Caucasian female
height, 165 cm; weight, 62 kg) with a history of
ecurrent urinary tract infections presented with
ecent symptoms of dyspnea, fatigue and produc-
ive cough. Three days earlier, she was started on
itrofurantoin 100mg orally three times per day
or the treatment of a recent urinary tract infec-
ion. Culture results grew Escherichia coli resistanttrain was susceptible to nitrofurantoin, trimetho-
rim/sulfamethoxazole, fosfomycin, aminoglyco-
ides, carbapenems, cefepime and ceftazidime.
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Table 1 Laboratory test results upon presentation.
Laboratory test results Normal range
Serum creatinine (mg/dL) 0.9 0.52—1.04
White blood cell count (×103/mm3) 13,500 5200—12,400
Platelet count 510,000 130,000—400,000
Differential
Eosinophils (%) 10% 0—7
Hemoglobin (g/dl) 12.4 12—16
Hematocrit (%) 38 37—47
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fhe was a non-smoker with no occupational expo-
ure and was allergic to penicillin and aspirin.
he patient was afebrile, and she developed a
ough associated with yellow sputum in addition
o dyspnea, decreased oral intake and general-
zed fatigue. Her past medical history included
ubacute thyroiditis, cystocele repair 10 years
go and a gynecological illness treated by hys-
erectomy in 1970 after which she had recurrent
rinary tract infections. She had a previous uri-
ary tract infection few months ago for which she
eceived nitrofurantoin. Upon examination, chest
uscultation revealed bilateral inspiratory crack-
es. Chest radiograph showed bilateral airspace
nd interstitial inﬁltrates. A computed tomogra-
hy scan of the chest showed diffuse bronchiectatic
hanges with bronchial wall dilatation predomi-
antly over the lower lobes, mild bilateral pleural
ffusion, bilateral posterobasal patchy ground-
lass and reticular inﬁltrates associated with areas
f consolidation, suggestive of an alveolar on
op of interstitial process. Diffuse subpleural ﬁne
eticular thickening was also noted. In addi-
ion to nitrofurantoin, the patient only received
multivitamin supplement. Laboratory studies
evealed an elevated white blood cell count
f 13,500/L (reference range = 5200—12,400/L)
nd blood eosinophilia (10%, reference range:
—7%). Electrolyte panel, renal function and car-
iac workups were normal. The patient’s urinalysis
as signiﬁcant for hazy turbidity, many squamous
pithelial cells and numerous bacteria. Laboratory
est results from her hospital stay are shown in
able 1.
The working diagnosis was nitrofurantoin-
nduced lung injury with a differential diagnosis of
ypersensitivity or chemical pneumonitis, atypical
neumonia and acute interstitial pneumonia.
itrofurantoin was discontinued and the patient
as started on Moxiﬂoxacin 400mg intravenously
er day. The patient’s symptoms and white blood
ell count normalized after 5 days while the
osinophil count remained elevated.
m
h
a
miscussion
itrofurantoin, a 5-nitrofuran derivative, is a ﬁrst
ine option for the treatment of uncomplicated uri-
ary tract infections in female patients [1]. The
ackage insert of nitrofurantoin does warn against
hronic, subacute or acute pulmonary hypersen-
itivity reactions that may occur and describes
hem brieﬂy [18]. However, these symptoms are
ell-described in the literature, which contains
any reports of acute cases of pulmonary toxic-
ty in patients receiving therapy with nitrofurantoin
2—9]. Indeed, signiﬁcant side effects from the
se of nitrofurantoin have been reported since
he 1960s, and these include a spectrum of dose-
ndependent lung disease [2—9]. The acute reaction
s thought to represent a hypersensitivity reac-
ion that often resolves upon drug withdrawal,
hereas in the chronic form, nitrofurantoin has
een reported to cause a reaction reﬂecting an
llergic or toxic response. Acute reactions occur in
pproximately 1 in 5000 patients after ﬁrst expo-
ure and are thus qualiﬁed as rare. They are more
ommon in middle-aged or elderly female patients
r female patients with a structural abnormality
f the genitourinary tract who are likely to have
ecurrent urinary tract infections [7,11].
Acute pulmonary reactions often develop within
—8 days of starting nitrofurantoin but may appear
rom a few hours to 4 weeks after the ﬁrst dose.
he acute hypersensitivity reaction often presents
ith fever, dyspnea and cough. In the subacute
nd chronic reactions, the most common symptoms
re dyspnea and cough, which develop after at
east 1 month of treatment [7,12]. Upon physical
xamination, the patient usually appears acutely
ll with some degree of respiratory distress and
ften with cyanosis. Tachypnea, tachycardia, and
ever (temperature as high as 105 ◦F) are also com-
only present, and some patients may present with
ypotension. Bibasilar rales are common on chest
uscultation and chest radiographs may be nor-
al, but 90% include diffuse parenchymal changes
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or mixed interstitial alveolar shadowing, similar
to that of edema, in the lower zones. Pleural
effusions are also common [7]. CT ﬁndings in
nitrofurantoin-induced lung disease are reported as
bilateral ground glass opacities in the more acute
phase and a mixed picture of ground glass, consol-
idation and ﬁbrosis in chronic presentations [19].
White blood cell counts are usually normal or high,
but are rarely above 20× 103/mm3 (normal range
4—11× 103/mm3). Eosinophilia is also common but
may not be observed until a second reaction
occurs. Discontinuing nitrofurantoin often results in
a rapid decline in leukocytes and neutrophils, but
eosinophils may continue to increase for up to a
week after symptoms have resolved and can remain
elevated for as long as 6 weeks. The erythrocyte
sedimentation rate can also increase, sometimes up
to 80mm/h (normal range 0—30mm/h) [7].
Establishing a correct diagnosis, however, is
often difﬁcult to do, as most patients are admitted
to the hospital and initially treated for pneumonia,
myocardial infarction, pulmonary embolism, heart
failure, or other misdiagnosed disorders. Delaying
the correct diagnosis and initiating unrelated treat-
ments may increase morbidity and mortality [7].
Treatment of acute pulmonary toxicity involves
the prompt discontinuation of nitrofurantoin, which
should result in obvious clinical improvement in
the following 24 h. Chest radiograph ﬁndings and
eosinophilia may take longer to resolve. Other
treatments may also be needed, such as oxy-
gen, intubation and pressors, if indicated. A short
steroid course may also be beneﬁcial for certain
patients with severe reactions or for those whose
symptoms do not resolve after nitrofurantoin with-
drawal. Bronchodilators may be used for patients
with bronchospasms. Once the reaction is accu-
rately identiﬁed and nitrofurantoin is discontinued,
the prognosis is usually very good [7], with an over-
all mortality rate of only 0.5% [20]. In contrast with
the chronic reaction, which is generally believed
to have a toxic mechanism [19], acute pulmonary
reactions are generally considered to be hyper-
sensitivity reactions because of symptoms such
as fever, eosinophilia, reappearance of symptoms
within hours of subsequent nitrofurantoin expo-
sure, and rapid resolution of pulmonary inﬁltrates
after nitrofurantoin withdrawal [7]. However, the
exact mechanism remains undetermined. The pro-
posed mechanisms involve a cytotoxic response,
an immune-complex mediated response and a cell-
mediated reaction [7].With a score of 7 according to the Naranjo
adverse drug reaction probability scale, it is highly
probable that our patient experienced an acute pul-
monary reaction to nitrofurantoin. This reaction isW.K. Kabbara, M.C. Kordahi
ell documented in the medical literature; similar
o other cases, our patient was initially diagnosed
ith pneumonia, and there was a gradual resolution
f her symptoms over the next few days after the
iscontinuation of nitrofurantoin.
It is also interesting to note that our patient also
ook a course of nitrofurantoin 7 months ago for the
reatment of a urinary tract infection and devel-
ped bronchitis. Moreover, when calculated using
he Cockcroft—Gault equation, the patient’s cre-
tinine clearance was less than 60mL/min. These
ndings, added to the fact that the patient is an
lder female with structural abnormality of the
enitourinary tract, contributed to the risk of acute
ung injury induced by nitrofurantoin.
onclusion
his case report brings to light the recognized
dverse respiratory impact of nitrofurantoin use,
well-documented but rare risk that is often mis-
iagnosed, resulting in unnecessary treatment and
onger hospital stay. It is thus important that cli-
icians should be aware of the spectrum of side
ffects from the use of nitrofurantoin, rendering
he correlation between its use and morbidity less
lusive. To effectively reduce the morbidity and
ortality associated with the use of nitrofurantoin,
t is our role as pharmacists to properly counsel
atients about pulmonary reactions before therapy
s started and to stress that the patient promptly
eports any unusual symptoms.
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